Bird & Bird advised Lonza, while Goodwin and NautaDutilh advised Synaffix. SynAffix B.V. announced the sale to Lonza Group AG. Under the terms of the sale and...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Synaffix on the deal. Synaffix announced a licensing agreement with Amgen to develop next generation of antibody-drug conjugates (ADCs) using Synaffix technology. Under the...
You must be a Standard 1 Year member to access this content.
Goodwin advised Syndesi Therapeutics on the deal. Deloitte Legal assisted the selling shareholders and the company with the sale of Syndesi Therapeutics. Syndesi annouunced its acquisition by...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Genfit on the deal. Genfit entered into a licensing agreement with Genoscience Pharma for exclusive right to develop and commercialize the investigational treatment...
You must be a Standard 1 Year member to access this content.
IN BRIEF: Bird & Bird, Foley Hoag LLP, Goodwin Procter, advised on the matter. Bird & Bird advised SparingVision SAS with a team including Emmanuelle Porte...
You must be a Standard 1 Year member to access this content.
